5FU is a fluoropyrimidine used for the treatment of solid tumors. 5FU is a precursor of dTTP and UTP during biogenesis, and it interferes with both DNA and RNA metabolism. The RNA exosome, a multisubunit complex with ribonucleaolytic activity, has been identified as one of the targets of 5FU in yeast. Studies in human cells have shown that the catalytic subunit of the nuclear exosome, Rrp6, is specifically targeted. Here we have investigated the direct effect of 5FU on the activity of Rrp6 in Drosophila S2 cells, and we have identified two aspects of Rrp6 function that are altered by 5FU. First, gel filtration analysis revealed that the repertoire of multimolecular complexes that contain Rrp6 is modified by exposure to 5FU, which is consistent with the proposal that incorporation of 5FU into RNA leads to the sequestration of Rrp6 in ribonucleoprotein complexes. Second, the incorporation of 5FU into RNA renders the RNA less susceptible to degradation by Rrp6, as shown by Rrp6 activity assays in vitro. Our results imply that aberrant transcripts synthesized in 5FU-treated cells cannot be turned over efficiently by the surveillance machinery. Together with previous results on the mechanisms of action of 5FU, our findings suggest that the cytotoxicity of 5FU at the RNA level is the result of at least three different effects: the increased levels of retroviral transcripts with mutagenic potential, the reduced synthesis of ribosomes, and the inhibition of the nuclear RNA surveillance pathways. Drugs that reinforce any of these effects may boost the cytotoxicity of 5FU.
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Introduction
The pyrimidine analog 5-fluorouracil (5FU) is widely used in the treatment of solid tumors, including colorectal and breast cancers. After penetration into the cell, 5FU is converted into 5-fluorodeoxyuridine 5'-monophosphate (5FdUMP) and 5-fluorouridine 5'-monophosphate (5FUMP), both of which can be further phosphorylated and incorporated into DNA and RNA, respectively (reviewed by 1).
Multiple mechanisms contribute to the anti-proliferative activity of 5FU (reviewed by 2). First, 5FUMP associates with 5,10-methylene tetrahydrofolate and with thymidylate synthase (TS) and forms an inactive TS complex. TS is a key enzyme in the de novo synthesis of thymidylate, and the inactivation of TS by 5FUMP leads to reduced levels of dTTP and to inhibition of DNA replication. Second, the reduced activity of TS results in abnormally high levels of dUTP, and both dUTP and 5FdUTP then become misincorporated into DNA, instead of dTTP. Excision of the misincorporated 5FU derivatives by uracil-DNA-glycosylase results in DNA damage and cell death (3) . And third, FUTP is extensively incorporated into RNA, which inhibits the processing and maturation of rRNA, tRNA and mRNA precursors (4-7).
The extent to which each of the pathways mentioned above contributes to the cytotoxicity of 5FU probably varies among cancer types, individual genetic backgrounds and administration schemes. TS is thought to be the main target of 5FU.
However, a pharmacological analysis that compiled gene expression profiles for human cancer cell lines treated with different drugs showed that 5FU clusters with inhibitors of RNA synthesis (8) , which suggests that RNA-mediated mechanisms contribute significantly to the therapeutic properties of 5FU. A genome-wide screen aimed at discovering the modes of action of several therapeutic compounds using yeast heterozygotes identified eight potential targets for 5FU and, interestingly, four of them were subunits of the exosome (9) . The exosome is a multiprotein complex with ribonucleolytic activity that plays several important roles in RNA metabolism. In the cytoplasm, the exosome has degradative functions and is responsible for mRNA turnover. In the cell nucleus, the exosome participates in the processing and maturation of small non-coding RNAs and pre-rRNAs, and in the quality control of mRNA biogenesis (reviewed by [10] [11] [12] . The exosome associates with different multiprotein complexes and interacts with different specific cofactors when carrying out its different functions (13).
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The exosome has a ring-shaped core composed of nine protein subunits. Two additional subunits, Rrp6 and Dis3, interact with the exosome ring and provide the ribonucleolytic activity (14) . Structural and biochemical studies have shown that the structure and function of the exosome are highly conserved throughout evolution from yeast to man (15 and references therein). The components of the exosome of Drosophila melanogaster have been identified, and are very similar to their human counterparts (16) . Studies in D. melanogaster revealed that Rrp6 not only works in association with the exosome ring, it also has exosome-independent functions in cell cycle regulation and mitotic progression (17) .
A recent study has shown that human cells depleted of the exosome subunit Rrp6 are more sensitive to 5FU than control cells with full Rrp6 activity, and that the levels of natural exosome substrates (such as endogenous retroviral transcripts) are increased by the 5FU treatment. These results confirm that Rrp6 is indeed a target for 5FU in human cells (18) . However, we do not know the molecular mechanisms by which 5FU affects the function of Rrp6. We have addressed this question by analyzing the effect of 5FU on two aspects of Rrp6 function in order to increase our understanding of the cytotoxicity of 5FU. These aspects are the incorporation of Rrp6 into multiprotein complexes in vivo and the Rrp6 exoribonuclease activity in vitro. We have used Drosophila S2 cells as a model system and we have produced epitopetagged Rrp6 that we have used for activity assays in vitro. Our results show that RNA molecules that contain 5FU instead of uracil are not degraded by Rrp6 as efficiently as normal RNA is degraded. We discuss a revised model for the mechanism of action of 5FU in vivo. 
Materials and Methods

Culture of Drosophila S2 cells
D. melanogaster S2 cells were cultured at 28 °C according to the instructions of the Drosophila Expression System manual from Invitrogen. Cells stably transfected with a plasmid that encodes V5-tagged Rrp6 have been described by Hessle et al. (19) . The mock cells used in this study are S2 cells stably transfected with the hygromycin selection plasmid but without the Rrp6-V5 expression plasmid. The cells were maintained in the presence of 300 µg/ml hygromycin B. Expression of Rrp6-V5 was induced with treatment with CuSO 4 for 24 hours.
Antibodies
The anti-V5 antibody was a monoclonal antibody from Invitrogen. The anti- 
Purification of RNA synthesized in vivo
RNA was purified using TRIzol (Invitrogen) from Drosophila S2 cells that had been exposed to 20 µM uracil or 5-fluorouracil for 24 hours. The resulting RNA was extracted by phenol, precipitated and resuspended in RNAse-free water.
In vitro transcription
RNA was generated in vitro by using T7 polymerase (Invitrogen) to transcribe a PCR amplified fragment of EGFP designed to add the T7 promoter to the 5' end (T7+Forward: taatacgactcactatagggagATGGTGAGCAAGGGCGAGGAGCTG;
Reverse: GCGGTCACGAACTCCAGCAG). The manufacturer's conditions for polymerization were followed with the exception that the UTP concentration was lowered to 1 mM (from 2 mM; ATP, CTP, GTP remained at 2 mM each). RNA into which 5F-UTP had been incorporated was generated by resuspending 5-fluorouridine 5'-triphosphate tetraammonium salt (5F-UTP, Moravek Biochemicals Inc., Brea, California) in water and including it in the reaction (0.35 mM 5F-UTP) while the levels of UTP were adjusted accordingly (0.65 mM UTP). After transcription, the 7 reaction products were digested with Turbo DNAse (Ambion) and precipitated with ethanol.
In vitro Rrp6 activity assay
Cells expressing Rrp6-V5 and mock S2 cells were induced for 24 h with 400 µM CuSO 4 prior to extraction of nuclear proteins as described above, with additional attention paid to keeping the extracts in RNAse-free conditions. Extracts were precleared with a mixture of protein A-coupled and protein G-coupled Sepharose beads previously equilibrated in lysis buffer. The pre-cleared extracts were then incubated for 1 hour with 15 µg/ml anti-V5 antibody (Invitrogen). Protein A/G Sepharose bead slurry was added to the extracts, and the mixture was incubated again for 1 hour. The beads with bound Rrp6-V5 were extensively washed with lysis buffer. The washed beads were resuspended in 100 µl lysis buffer containing 50% glycerol and stored at - 
Results
5FU affects the association of Rrp6 with multimolecular complexes
Rrp6 is a target for 5FU in human cells (18) but the molecular mechanisms of 5FU cytotoxicity have not been fully elucidated. To address this question, we carried out a first series of experiments in which we analyzed whether the assembly of Rrp6 into multimolecular complexes in vivo was affected by 5FU. We used Drosophila S2 cells that expressed a V5-tagged version of Rrp6 under the control of a metallothionein promoter (19) . The expression of the tagged Rrp6 was induced with copper sulfate, as shown in Figure 1A . Several observations indicated that the presence of the V5 tag in Rrp6 did not affect the function of the tagged Rrp6 protein.
Firstly, the growth of S2 cells was not inhibited by the expression of the tagged Rrp6 (data not shown). Secondly, the tagged Rrp6 was predominantly localized in the cell nucleus ( Figure 1B ), as described for the endogenous Rrp6 (20) . And thirdly, we showed in a previous study that Rrp6-V5 associates in vivo with proteins such as Spt5 and Spt6, which are known to interact with the endogenous exosome (16, 19) . Figure 2B ). Virtually no free Rrp6 protein was detected in the conditions of our experiment. Rrp6 was detected in a variety of complexes of molecular masses between 400 and 800 kDa, and was particularly enriched in complexes of molecular masses approximately 750, 600 and 440 KDa, respectively (arrowheads in Figure   2B ). A low-abundance complex larger than 2 MDa was also present (see Fractions 3-5 in Figure 2B ). This fractionation pattern was reproducible. The relative abundance of Rrp6 in each fraction was determined by densitometric analysis of Western blots like the one shown in Figure 2B . The chart in Figure 2D We used an antibody against the exosome ring subunit Ski6 to identify the exosome-containing fractions. Figure 2B shows that Ski6 was mostly concentrated in a complex of molecular mass 600 kDa. We concluded, based on this observation and on the expected size of the nuclear exosome in vivo (21) , that the 600 kDa complex contained the entire nuclear exosome. Trf4, a subunit of the TRAMP complex, was also found in the fractions in the 600 kDa range. Trf4 is not a component of the exosome but contributes to enhance the hydrolytic activity of the nuclear exosome on highly structured RNA substrates (22) , and therefore the Trf4 fractionation pattern is expected to partially overlap with that of the exosome. In summary, we conclude that Figures 2C and 2D, dashed line) . The nuclear exosome complex, again defined by the presence of Ski6, had been shifted from 600 kDa to approximately 500 kDa. Trf4 also showed a shift towards the 500 kDa region (Fraction 31 in Figure 2C ).
The compositions of the different Rrp6-containing complexes are not known, which precludes a detailed interpretation of the molecular interactions that are affected by 5FU. However, our present results clearly demonstrate that the treatment of cells with 5FU has a direct effect on the association of Rrp6 with multimolecular complexes in the cell nucleus. Among the observed effects of 5FU, we detected a change in the relative molecular mass of the complex that contains both Rrp6 and the core exosome. 
Establishment of an in vitro system to assay the ribonucleolytic activity of Rrp6
In another series of experiments, we sought to analyze the effect of 5FU on the ribonucleolytic activity of Rrp6. For this purpose, we first established an in vitro assay for Rrp6 activity. We induced the expression of Rrp6 in S2 cells, we prepared nuclear protein extracts and we isolated Rrp6 using the anti-V5 antibody. The quality of the immuno-precipitated Rrp6 was analyzed by SDS-PAGE and Coomassie staining ( Figure 3A) . Apart from the heavy and light chains of the antibody (H and L in Figure 3A) , Rrp6 was the main immuno-precipitated protein (asterisk in Figure   3A ). Mock enzyme preparations were obtained in parallel using S2 cells that had been transfected with a resistance plasmid but without the Rrp6 expression plasmid (for details see Materials and Methods). The mock enzyme preparations were used in all subsequent assays to discriminate between Rrp6-mediated ribonucleolysis and unspecific RNA degradation.
The two catalytic subunits of the exosome, Dis3 and Rrp6, interact with each other in vivo (23) and we considered the possibility that Dis3 was present as a contaminant in our Rrp6 preparations. For this reason, all the activity assays were carried out in the presence of 7 mM Mg 2+ , which inhibits Dis3 (24).
The enzymatic activity of the immuno-precipitated Rrp6 protein was assayed using total RNA purified from S2 cells as a substrate. This RNA synthesized in vivo and purified from S2 cells constituted a source of physiologically relevant substrate for the in vitro activity assays. The reaction mixtures were incubated at 30 °C for 1 hour, and the reaction products were purified and analyzed using microfluidic chips in an automated electrophoresis system. The results of the electrophoretic analysis were visualized as either simulated gels ( Figure 3B ) or electropherograms ( Figure 3C ). An example of total RNA digested with Rrp6 is shown in Figures 3B and C . The two intense bands of lengths approximately 2000 nt correspond to the rRNAs (asterisk in Figure 3B ). The mock-digested RNA preparations were not significantly digested and their electrophoretic profile was very similar to that of the input undigested RNA (compare Lanes 1 and 2 in Figure 3B ). The RNA samples digested with Rrp6, in contrast, were significantly degraded (compare Lanes 2 and 3 in Figure 3B , and Figure 3C ). In summary, these results show that the Rrp6 preparations isolated from S2 cells were active in vitro and could be used in activity assays.
rRNA synthesized in vivo in the presence of 5FU is not efficiently degraded by Rrp6
One of the mechanisms of action of 5FU involves the conversion of 5FU into 5FUTP and its subsequent incorporation into RNA (reviewed by 1). The resulting RNA, from now on referred to as "5F-RNA", is not a proper substrate for some of the enzymes that are involved in pre-rRNA processing (see, for example, 7). Under normal growth conditions, defective rRNA molecules are identified by the surveillance machinery of the cell, and degraded by the nuclear exosome (11).
However, the rRNA intermediates accumulate in 5FU-treated cells (25) . We therefore sought to assess the ability of Rrp6 to degrade 5F-RNA synthesized in vivo. S2 cells were treated with 20 µM 5FU for 24 hours before purification of the total RNA.
Control cells were treated in parallel with the same concentration of uracil (Ura). The RNA made by Ura-treated cells was normal, non-modified RNA. Ura-RNA and 5F-RNA were used as substrates in the enzymatic assays similar to those described in Figure 3 . Figure 4 shows the electropherograms of mock-digested and Rrp6-digested samples. The electropherograms of the RNAs from mock digestions were very similar to those of undigested RNA, as expected, and the RNAs synthesized in the presence of Ura or 5FU were similar to each other (left panel in Figure 4A ). In contrast, the electropherograms of Ura-RNA and 5F-RNA digested with Rrp6 were significantly different. Both the Ura-RNA and the 5F-RNA were digested to some extent, as shown by the reduced abundance of the rRNA peaks (right panel in Figure 4A ). However, the digestion of 5F-RNA was not complete. 5F-RNA species in the 100-1900 nt range accumulated in the Rrp6-digested samples (see the low molecular mass region of the electropherogram in Figure 4A ), which suggests that the digestion of 5F-rRNA by Rrp6 is not as processive as the digestion of normal Ura-RNA is.
The electropherograms in Figure 4A show results from one experiment. We next quantified and compiled the results from three independent digestions ( Figure 4B ).
The amounts of RNA in the low molecular mass region and in the rRNA peak were quantified separately, and Figure 4B shows histograms of the averages. The accumulation of low molecular mass 5F-rRNA was significant and reproducible. The results presented above support the hypothesis that 5F-rRNA synthesized in vivo is not efficiently degraded by Rrp6. The disappearance of the rRNA peak suggests that 5F-rRNA is recognized as a substrate by Rrp6 and is degraded to some extent. However, the concomitant accumulation of RNA molecules of lower molecular mass indicates that digestion of 5F-rRNA by Rrp6 is not fully processive.
5F-RNA synthesized in vitro is not efficiently degraded by Rrp6
The incomplete digestion of 5F-rRNA reported above may have been caused directly by the presence of 5FU in the rRNA. Alternatively, the incorporation of 5FU into pre-rRNA in vivo may interfere with post-transcriptional modifications (reviewed by 26), which in turn could lead to the formation of aberrant rRNA species less susceptible to digestion by Rrp6. We carried out Rrp6 activity assays on 5F-RNA synthesized in vitro to determine whether the presence of 5FU in the RNA had a direct impact on the ribonucleolytic activity of Rrp6. We chose to use an mRNA sequence instead of an rRNA to minimize the formation of stable secondary structures that could affect the processivity of Rrp6 in vitro. We synthesized an mRNA molecule of 750 nt by in vitro transcription in the presence of 5F-UTP as described in Materials and Methods. The same mRNA sequence containing normal uridine was synthesized in parallel and used as a reference. Both the normal RNA and the 5F-RNA were digested by Rrp6 to some extent, but quantification of the reaction products revealed that digestion of the 5F-RNA was less efficient ( Figure 5 ). We conclude that the presence of 5FU in RNA is sufficient to render the RNA more resistant to digestion by Rrp6. 
Discussion
5FU is widely used in combination therapies for the treatment of a variety of cancers, including colorectal cancer (reviewed by 27). Resistance to 5FU, however, arises relatively often and limits the use of this drug. Understanding the mechanisms of 5FU cytotoxicity is an important step towards the development of new strategies to minimize drug resistance. 5FU was originally designed to inhibit DNA replication by blocking the de novo synthesis of thymidylate (28) . However, 5FU is also incorporated into RNA and alters RNA metabolism through mechanisms that are not fully understood (reviewed by 2). The human Rrp6 protein has recently been identified as a target for 5FU (18) . We have now investigated the direct effect of 5FU on the activity of Rrp6 and we have identified two aspects of Rrp6 function that are altered in 5FU-treated cells. First, the repertoire of multimolecular complexes that contain Rrp6 is modified by the exposure of cells to 5FU. The molecular mass of the nuclear exosome is altered, which suggests that its composition or its association with other factors is modified. This observation is consistent with the suggestion that incorporation of 5FU into RNA leads to sequestration of Rrp6 (7, 18) . Second, the ribonucleolytic activity of Rrp6 is less efficient on RNA that contains 5FU than it is on normal RNA. This is a direct effect of the incorporation of 5FU into RNA that can be measured in vitro under conditions in which the influence of other activities or processes, such as RNA post-transcriptional modifications, can be ruled out.
Early studies showed that the exposure of cells to 5FU inhibits the processing of pre-rRNA (29) . In vitro experiments based on the use of mouse cell extracts revealed that the incorporation of 5FU into pre-rRNA did not have a direct effect on premRNA processing, but that the ability of cell extracts to catalyze pre-rRNA cleavage reactions was impaired by the 5FU treatment (6) . This observation led to the proposal that inhibition of pre-rRNA processing by 5FU was due to the inactivation of a transacting processing factor (6) . In a recent study (7), Hoskins and Butler have implicated the activity of the yeast rRNA pseudouridylase Cbf5p in the cytotoxicity of 5FU, and have suggested that Cbf5p forms stable adducts with 5F-RNA in cells treated with 5FU. The toxic effect of 5FU may thus be partly mediated by the sequestration of pseudouridylases in inactive ribonucleoprotein complexes (7) . In such a scenario, psuedouridylation reactions would be inhibited and the 5F-RNA bound to pseudouridylases would be degraded by Rrp6 and the nuclear exosome. However, the In summary, the cytotoxic activity of 5FU at the RNA level is the result of at least three effects: the increased levels of retroviral elements with mutagenic potential, the reduced synthesis of ribosomes, and the inhibition of the nuclear RNA surveillance pathway. Drugs that reinforce any of these effects will probably boost the cytotoxic activity of 5FU. deviations. The digestion of the rRNA peaks was as effective for control Ura-rRNA as for 5F-rRNA. There was a significant accumulation of 5F-RNA intermediates of 100-1900 nt that was not observed in Ura-RNA (non-parametric two-tailed MannWhitney U test for Ura vs. 5FU in the low region, p = 0.001). 
